BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment
BiVictriX Therapeutics plc (AIM: BVX), a pioneering drug discovery and development company, has announced receiving a substantial grant of £0.37 million from Innovate UK. This ... Read More
BiVictriX Therapeutics receives FDA orphan drug designation for BVX001 in AML
BiVictriX Therapeutics plc (AIM: BVX), a prominent UK-based biotechnology firm, has reached a pivotal regulatory milestone as the US Food and Drug Administration (FDA) has ... Read More